Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
motexafin gadolinium + rituximab + ibritumomab tiuxetan (Northwestern University)
- Development stage
- Unknown
- Lead developer
- Biogen
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy, evaluated in a Phase I/II trial at Northwestern University, integrates the redox-modulating agent motexafin gadolinium (Xcytrin) with the standard Zevalin radioimmunotherapy regimen for relapsed or refractory CD20-positive non-Hodgkin's lymphoma. The Zevalin regimen consists of the anti-CD20 murine monoclonal antibody ibritumomab tiuxetan, which is sequentially labeled with Indium-111 for biodistribution imaging and Yttrium-90 for targeted beta-radiation therapy, preceded by rituximab to optimize antibody distribution. Motexafin gadolinium acts as a radiosensitizer by disrupting cellular redox processes and increasing oxidative stress, thereby enhancing the cytotoxic effects of the Yttrium-90 radiation on lymphoma cells.
- Other names
- 111Indium-Zevalin90Yttrium-Zevalinibritumomab tiuxetanmotexafin gadoliniumrituximabZevalin regimen
02
Targets
Beyond the preview
Go deeper on motexafin gadolinium + rituximab + ibritumomab tiuxetan (Northwestern University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on motexafin gadolinium + rituximab + ibritumomab tiuxetan (Northwestern University).